DATA GRAPHICS | Data Byte
Pace of biotech-SPAC mergers remains steady in 2H22
SPACs continue to be a viable IPO alternative, with at least 10 biotechs expecting to start trading in 1H23
December 21, 2022 11:06 PM UTC
At least 14 biotechs saw mergers with special purpose acquisition companies as a viable path to the public market in 2H22. Two had their deals terminated, while two others have started trading and the rest aim to do so in 1H23.
The 14 biotech-SPAC mergers announced in 2H22 nearly matched the 15 announced in the first half of the year, and put 2022’s total at five more than 2021’s 23 announcements. ...